title: Gatekeeper Mutations and Intratumoral Heterogeneity inFGFR2-Translocated Cholangiocarcinoma.
abstract: <b/>FGFR2genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and colleagues demonstrates that acquisition of gatekeeper mutations inFGFR2and intratumoral heterogeneity drive resistance in patients withFGFR2-translocated intrahepatic cholangiocarcinoma, which will have important implications for management of the disease in clinic.Cancer Discov; 7(3); 248-9. ©2017 AACR.See related article by Goyal et al., p. 252.
authors.affiliation: Department of Gastrointestinal Oncology, Royal Marsden Hospital, London, United Kingdom.
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Smyth
authors.affiliation: Molecular Oncology, Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
authors.forename: Irina S
authors.initials: IS
authors.lastname: Babina
authors.affiliation: Molecular Oncology, Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom. Nick.Turner@icr.ac.uk.|Breast Unit, The Royal Marsden Hospital, NHS Foundation Trust, London, United Kingdom.
authors.forename: Nicholas C
authors.initials: NC
authors.lastname: Turner
mesh_terms: D001650:Bile Duct Neoplasms / Q000235:genetics; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma / Q000235:genetics*; D006801:Humans; D008113:Liver Neoplasms; D009154:Mutation; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000235:genetics*
chemical_list: D051497:Receptor, Fibroblast Growth Factor, Type 2